Constantinos Zamboglou1,2, Gesche Wieser3, Steffen Hennies4, Irene Rempel5, Simon Kirste6,7, Martin Soschynski5, Hans Christian Rischke6, Tobias Fechter6,7, Cordula A Jilg8, Mathias Langer5, Philipp T Meyer7,3, Michael Bock7,5, Anca-Ligia Grosu6,7. 1. Department of Radiation Oncology, University Medical Center Freiburg, Robert-Koch Straße 3, 79106, Freiburg, Germany. constantinos.zamboglou@uniklinik-freiburg.de. 2. German Cancer Consortium (DKTK), Partner Site Freiburg, Heidelberg, Germany. constantinos.zamboglou@uniklinik-freiburg.de. 3. Department of Nuclear Medicine, University Medical Center Freiburg, Freiburg, Germany. 4. Department of Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany. 5. Department of Radiology, University Medical Center Freiburg, Freiburg, Germany. 6. Department of Radiation Oncology, University Medical Center Freiburg, Robert-Koch Straße 3, 79106, Freiburg, Germany. 7. German Cancer Consortium (DKTK), Partner Site Freiburg, Heidelberg, Germany. 8. Department of Urology, University Medical Center Freiburg, Freiburg, Germany.
Abstract
PURPOSE: Multiparametric magnetic resonance imaging (mpMRI) is widely used in radiation treatment planning of primary prostate cancer (PCA). Focal dose escalation to the dominant intraprostatic lesions (DIPL) may lead to improved PCA control. Prostate-specific membrane antigen (PSMA) is overexpressed in most PCAs. (68)Ga-labelled PSMA inhibitors have demonstrated promising results in detection of PCA with PET/CT. The aim of this study was to compare (68)Ga-PSMA PET/CT with MRI for gross tumour volume (GTV) definition in primary PCA. METHODS: This retrospective study included 22 patients with primary PCA analysed after (68)Ga-PSMA PET/CT and mpMRI. GTVs were delineated on MR images by two radiologists (GTV-MRIrad) and two radiation oncologists separately. Both volumes were merged leading to GTV-MRIint. GTVs based on PET/CT were delineated by two nuclear medicine physicians in consensus (GTV-PET). Laterality (left, right, and left and right prostate lobes) on mpMRI, PET/CT and pathological analysis after biopsy were assessed. RESULTS: Mean GTV-MRIrad, GTV-MRIint and GTV-PET were 5.92, 3.83 and 11.41 cm(3), respectively. GTV-PET was significant larger then GTV-MRIint (p = 0.003). The MRI GTVs GTV-MRIrad and GTV-MRIint showed, respectively, 40 % and 57 % overlap with GTV-PET. GTV-MRIrad and GTV-MRIint included the SUVmax of GTV-PET in 12 and 11 patients (54.6 % and 50 %), respectively. In nine patients (47 %), laterality on mpMRI, PET/CT and histopathology after biopsy was similar. CONCLUSION: Ga-PSMA PET/CT and mpMRI provided concordant results for delineation of the DIPL in 47 % of patients (40 % - 54 % of lesions). GTV-PET was significantly larger than GTV-MRIint. (68)Ga-PSMA PET/CT may have a role in radiation treatment planning for focal radiation to the DIPL. Exact correlation of PET and MRI images with histopathology is needed.
PURPOSE: Multiparametric magnetic resonance imaging (mpMRI) is widely used in radiation treatment planning of primary prostate cancer (PCA). Focal dose escalation to the dominant intraprostatic lesions (DIPL) may lead to improved PCA control. Prostate-specific membrane antigen (PSMA) is overexpressed in most PCAs. (68)Ga-labelled PSMA inhibitors have demonstrated promising results in detection of PCA with PET/CT. The aim of this study was to compare (68)Ga-PSMA PET/CT with MRI for gross tumour volume (GTV) definition in primary PCA. METHODS: This retrospective study included 22 patients with primary PCA analysed after (68)Ga-PSMA PET/CT and mpMRI. GTVs were delineated on MR images by two radiologists (GTV-MRIrad) and two radiation oncologists separately. Both volumes were merged leading to GTV-MRIint. GTVs based on PET/CT were delineated by two nuclear medicine physicians in consensus (GTV-PET). Laterality (left, right, and left and right prostate lobes) on mpMRI, PET/CT and pathological analysis after biopsy were assessed. RESULTS: Mean GTV-MRIrad, GTV-MRIint and GTV-PET were 5.92, 3.83 and 11.41 cm(3), respectively. GTV-PET was significant larger then GTV-MRIint (p = 0.003). The MRI GTVs GTV-MRIrad and GTV-MRIint showed, respectively, 40 % and 57 % overlap with GTV-PET. GTV-MRIrad and GTV-MRIint included the SUVmax of GTV-PET in 12 and 11 patients (54.6 % and 50 %), respectively. In nine patients (47 %), laterality on mpMRI, PET/CT and histopathology after biopsy was similar. CONCLUSION: Ga-PSMA PET/CT and mpMRI provided concordant results for delineation of the DIPL in 47 % of patients (40 % - 54 % of lesions). GTV-PET was significantly larger than GTV-MRIint. (68)Ga-PSMA PET/CT may have a role in radiation treatment planning for focal radiation to the DIPL. Exact correlation of PET and MRI images with histopathology is needed.
Authors: H Christian Rischke; Teresa Beck; Werner Vach; Gesche Wieser; Anca L Grosu; Wolfgang Schultze-Seemann; Philipp T Meyer; Cordula A Jilg Journal: Eur J Nucl Med Mol Imaging Date: 2014-06-21 Impact factor: 9.236
Authors: Sebastian Mannweiler; Peter Amersdorfer; Slave Trajanoski; Jonathan A Terrett; David King; Gabor Mehes Journal: Pathol Oncol Res Date: 2008-09-18 Impact factor: 3.201
Authors: Simon R J Bott; Hashim U Ahmed; Richard G Hindley; Ahmad Abdul-Rahman; Alex Freeman; Mark Emberton Journal: BJU Int Date: 2010-12 Impact factor: 5.588
Authors: Ken Herrmann; Christina Bluemel; Martina Weineisen; Margret Schottelius; Hans-Jürgen Wester; Johannes Czernin; Uta Eberlein; Seval Beykan; Constantin Lapa; Hubertus Riedmiller; Markus Krebs; Saskia Kropf; Andreas Schirbel; Andreas K Buck; Michael Lassmann Journal: J Nucl Med Date: 2015-04-16 Impact factor: 10.057
Authors: Markus Dietlein; Carsten Kobe; Georg Kuhnert; Simone Stockter; Thomas Fischer; Klaus Schomäcker; Matthias Schmidt; Felix Dietlein; Boris D Zlatopolskiy; Philipp Krapf; Raphael Richarz; Stephan Neubauer; Alexander Drzezga; Bernd Neumaier Journal: Mol Imaging Biol Date: 2015-08 Impact factor: 3.488
Authors: Hans Christian Rischke; Ursula Nestle; Tobias Fechter; Christian Doll; Natalja Volegova-Neher; Karl Henne; Jutta Scholber; Stefan Knippen; Simon Kirste; Anca L Grosu; Cordula A Jilg Journal: Radiat Oncol Date: 2013-07-22 Impact factor: 3.481
Authors: Simona Malaspina; Ugo De Giorgi; Jukka Kemppainen; Angelo Del Sole; Giovanni Paganelli Journal: Radiol Med Date: 2018-08-16 Impact factor: 3.469
Authors: Ivan Jambor; Anna Kuisma; Esa Kähkönen; Jukka Kemppainen; Harri Merisaari; Olli Eskola; Jarmo Teuho; Ileana Montoya Perez; Marko Pesola; Hannu J Aronen; Peter J Boström; Pekka Taimen; Heikki Minn Journal: Eur J Nucl Med Mol Imaging Date: 2017-11-16 Impact factor: 9.236
Authors: Lena Thomas; Steffi Kantz; Arthur Hung; Debra Monaco; Florian C Gaertner; Markus Essler; Holger Strunk; Wolfram Laub; Ralph A Bundschuh Journal: Eur J Nucl Med Mol Imaging Date: 2018-02-21 Impact factor: 9.236
Authors: Benedict Oerther; Moritz V Buren; Christina M Klein; Simon Kirste; Nils H Nicolay; Tanja Sprave; Simon Spohn; Deepa Darshini Gunashekar; Leonard Hagele; Lars Bielak; Michael Bock; Anca-L Grosu; Fabian Bamberg; Matthias Benndorf; Constantinos Zamboglou Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155